A prospective, randomized, double-blinded, placebo-controlled study of human intravenous immunoglobulin for the acute management of presumptive primary immune-mediated thrombocytopenia in dogs

D. Bianco, P. J. Armstrong, R. J. Washabau

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background: Immune-mediated thrombocytopenia (IMT) is a common hematologic disorder in dogs. Human intravenous immunoglobulin (hIVIG) may have a beneficial effect in canine IMT. Hypothesis: A single hIVIG infusion (0.5 g/kg) in dogs with presumed primary IMT (pIMT) is a safe adjunctive emergency treatment to accelerate platelet count recovery and shorten hospitalization time without increasing the cost of patient care. Animals: Eighteen client-owned dogs with a presumptive diagnosis of pIMT. Methods: Prospective, randomized, double-blinded, placebo-controlled clinical trial. Results: There were no identifiable immediate or delayed adverse reactions associated with hIVIG administration over a 6-month period. The median platelet count recovery time for the hIVIG group was 3.5 days (mean SD: 3.7 1.3 days; range, 2-7 days) and 7.5 days (mean SD: 7.8 3.9 days; range, 3-12 days) for the placebo group. The median duration of hospitalization for hIVIG group was 4 days (mean SD: 4.2 0.4 days; range, 2-8 days) and 8 days (mean SD: 8.3 0.6 days; range, 4-12 days) for the placebo group. There was no significant difference between groups with respect to expense of initial patient care, whereas significant reduction in platelet count recovery time (P 5.018) and duration of hospitalization (P 5.027) were detected in the hIVIG group. Conclusions and Clinical Importance: Compared with corticosteroids alone, adjunctive emergency therapy of a single hIVIG infusion was safe and associated with a significant reduction in platelet count recovery time and duration of hospitalization without increasing the expense of medical care in a small group of dogs with presumed pIMT.

Original languageEnglish (US)
Pages (from-to)1071-1078
Number of pages8
JournalJournal of veterinary internal medicine
Volume23
Issue number5
DOIs
StatePublished - Sep 1 2009

Fingerprint

Idiopathic Thrombocytopenic Purpura
thrombocytopenia
Intravenous Immunoglobulins
immunoglobulins
placebos
Placebos
Dogs
blood platelet count
dogs
Platelet Count
Hospitalization
patient care
Emergency Treatment
Intravenous Infusions
duration
Patient Care
Controlled Clinical Trials
adrenal cortex hormones
Intravenous Administration
Canidae

Keywords

  • IMT
  • IVIG
  • Platelet
  • Prednisone
  • Vincristine

Cite this

@article{93569a6075174834b6d648c9931b5d35,
title = "A prospective, randomized, double-blinded, placebo-controlled study of human intravenous immunoglobulin for the acute management of presumptive primary immune-mediated thrombocytopenia in dogs",
abstract = "Background: Immune-mediated thrombocytopenia (IMT) is a common hematologic disorder in dogs. Human intravenous immunoglobulin (hIVIG) may have a beneficial effect in canine IMT. Hypothesis: A single hIVIG infusion (0.5 g/kg) in dogs with presumed primary IMT (pIMT) is a safe adjunctive emergency treatment to accelerate platelet count recovery and shorten hospitalization time without increasing the cost of patient care. Animals: Eighteen client-owned dogs with a presumptive diagnosis of pIMT. Methods: Prospective, randomized, double-blinded, placebo-controlled clinical trial. Results: There were no identifiable immediate or delayed adverse reactions associated with hIVIG administration over a 6-month period. The median platelet count recovery time for the hIVIG group was 3.5 days (mean SD: 3.7 1.3 days; range, 2-7 days) and 7.5 days (mean SD: 7.8 3.9 days; range, 3-12 days) for the placebo group. The median duration of hospitalization for hIVIG group was 4 days (mean SD: 4.2 0.4 days; range, 2-8 days) and 8 days (mean SD: 8.3 0.6 days; range, 4-12 days) for the placebo group. There was no significant difference between groups with respect to expense of initial patient care, whereas significant reduction in platelet count recovery time (P 5.018) and duration of hospitalization (P 5.027) were detected in the hIVIG group. Conclusions and Clinical Importance: Compared with corticosteroids alone, adjunctive emergency therapy of a single hIVIG infusion was safe and associated with a significant reduction in platelet count recovery time and duration of hospitalization without increasing the expense of medical care in a small group of dogs with presumed pIMT.",
keywords = "IMT, IVIG, Platelet, Prednisone, Vincristine",
author = "D. Bianco and Armstrong, {P. J.} and Washabau, {R. J.}",
year = "2009",
month = "9",
day = "1",
doi = "10.1111/j.1939-1676.2009.0358.x",
language = "English (US)",
volume = "23",
pages = "1071--1078",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - A prospective, randomized, double-blinded, placebo-controlled study of human intravenous immunoglobulin for the acute management of presumptive primary immune-mediated thrombocytopenia in dogs

AU - Bianco, D.

AU - Armstrong, P. J.

AU - Washabau, R. J.

PY - 2009/9/1

Y1 - 2009/9/1

N2 - Background: Immune-mediated thrombocytopenia (IMT) is a common hematologic disorder in dogs. Human intravenous immunoglobulin (hIVIG) may have a beneficial effect in canine IMT. Hypothesis: A single hIVIG infusion (0.5 g/kg) in dogs with presumed primary IMT (pIMT) is a safe adjunctive emergency treatment to accelerate platelet count recovery and shorten hospitalization time without increasing the cost of patient care. Animals: Eighteen client-owned dogs with a presumptive diagnosis of pIMT. Methods: Prospective, randomized, double-blinded, placebo-controlled clinical trial. Results: There were no identifiable immediate or delayed adverse reactions associated with hIVIG administration over a 6-month period. The median platelet count recovery time for the hIVIG group was 3.5 days (mean SD: 3.7 1.3 days; range, 2-7 days) and 7.5 days (mean SD: 7.8 3.9 days; range, 3-12 days) for the placebo group. The median duration of hospitalization for hIVIG group was 4 days (mean SD: 4.2 0.4 days; range, 2-8 days) and 8 days (mean SD: 8.3 0.6 days; range, 4-12 days) for the placebo group. There was no significant difference between groups with respect to expense of initial patient care, whereas significant reduction in platelet count recovery time (P 5.018) and duration of hospitalization (P 5.027) were detected in the hIVIG group. Conclusions and Clinical Importance: Compared with corticosteroids alone, adjunctive emergency therapy of a single hIVIG infusion was safe and associated with a significant reduction in platelet count recovery time and duration of hospitalization without increasing the expense of medical care in a small group of dogs with presumed pIMT.

AB - Background: Immune-mediated thrombocytopenia (IMT) is a common hematologic disorder in dogs. Human intravenous immunoglobulin (hIVIG) may have a beneficial effect in canine IMT. Hypothesis: A single hIVIG infusion (0.5 g/kg) in dogs with presumed primary IMT (pIMT) is a safe adjunctive emergency treatment to accelerate platelet count recovery and shorten hospitalization time without increasing the cost of patient care. Animals: Eighteen client-owned dogs with a presumptive diagnosis of pIMT. Methods: Prospective, randomized, double-blinded, placebo-controlled clinical trial. Results: There were no identifiable immediate or delayed adverse reactions associated with hIVIG administration over a 6-month period. The median platelet count recovery time for the hIVIG group was 3.5 days (mean SD: 3.7 1.3 days; range, 2-7 days) and 7.5 days (mean SD: 7.8 3.9 days; range, 3-12 days) for the placebo group. The median duration of hospitalization for hIVIG group was 4 days (mean SD: 4.2 0.4 days; range, 2-8 days) and 8 days (mean SD: 8.3 0.6 days; range, 4-12 days) for the placebo group. There was no significant difference between groups with respect to expense of initial patient care, whereas significant reduction in platelet count recovery time (P 5.018) and duration of hospitalization (P 5.027) were detected in the hIVIG group. Conclusions and Clinical Importance: Compared with corticosteroids alone, adjunctive emergency therapy of a single hIVIG infusion was safe and associated with a significant reduction in platelet count recovery time and duration of hospitalization without increasing the expense of medical care in a small group of dogs with presumed pIMT.

KW - IMT

KW - IVIG

KW - Platelet

KW - Prednisone

KW - Vincristine

UR - http://www.scopus.com/inward/record.url?scp=70349670886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349670886&partnerID=8YFLogxK

U2 - 10.1111/j.1939-1676.2009.0358.x

DO - 10.1111/j.1939-1676.2009.0358.x

M3 - Article

C2 - 19674280

AN - SCOPUS:70349670886

VL - 23

SP - 1071

EP - 1078

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 5

ER -